Management of Diarrhea in Colitis

Introduction to Colitis Management

The American Society of Clinical Oncology recommends avoiding antimotility agents like loperamide in patients with grade 3-4 diarrhea and colitis, as it can mask deterioration and delay appropriate immunosuppressive treatment 1
The National Comprehensive Cancer Network suggests treating the underlying inflammation with corticosteroids (1-2 mg/kg/day prednisone equivalent) and potentially biologics like infliximab or vedolizumab in patients with acute colitis 2, 3, 1

The assessment of diarrhea severity should include checking for fever, abdominal tenderness, bloody stools, or signs of acute inflammation, and ruling out infectious causes (C. difficile, bacterial pathogens) 3, 2
Fecal inflammatory markers (lactoferrin, calprotectin) should be obtained if available to guide treatment decisions 2, 3

For grade 1 diarrhea (<4 stools/day increase over baseline, no other symptoms), loperamide may be considered only after infection has been ruled out and no inflammatory markers are present, with close monitoring 2, 3
For grade 2 diarrhea (4-6 stools/day increase), immunotherapy should be held, and corticosteroids started; loperamide may be used only if diarrhea is present without colitis symptoms 2
For grade 3-4 diarrhea (≥7 stools/day or severe symptoms), loperamide should be absolutely avoided, and IV corticosteroids started at 1-2 mg/kg/day 1

Corticosteroids are the first-line treatment for grade ≥2 colitis, with the addition of infliximab 5 mg/kg if steroid-refractory after 3-5 days 2, 3, 1
Vedolizumab may be considered as a gut-specific alternative 3, 1

Loperamide should never be used to control diarrhea in acute colitis, as it masks the severity of inflammation and delays appropriate treatment 1
It is crucial to rule out C. difficile before using any antimotility agent, especially if antibiotics were recently used 3
The risk of toxic megacolon should be considered when using antimotility agents in acute colitis 4